Skip to content

Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

Randomized, Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03756779
Enrollment
0
Registered
2018-11-28
Start date
2017-05-15
Completion date
2020-06-30
Last updated
2018-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Hypercholesterolemia

Keywords

Diet study

Brief summary

We are performing a pilot cross-over diet study involving 5 patients with heterozygous FH and 5 patients with unexplained ADH. The patients will be randomized to a low versus high saturated fat diet for 4 weeks each. We hypothesize that patients with unexplained ADH may have an exaggerated cholesterol response to saturated fat intake. The specific aim of this study is to quantify the increase in LDL-C in unexplained ADH patients compared to FH patients. The pilot study proposed here will develop preliminary data to be used for future funding proposals of larger, randomized studies.

Interventions

OTHERDietary intervention

Dietary intervention with dietary modification of fat intake.

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Adults, age \> 18 years or \< 80 years 2. Pre-treatment LDL-C greater than the 95th percentile for age and sex (corresponding to 190 mg/dL for most adults), with one of the 2 following criteria: (1) tendon xanthoma (proband or first-degree relative) or (2) either first-degree relative with premature CHD (age less than 55 years in men or 65 years in women) or pretreatment LDL-C greater than the 95th percentile for age and sex. 3. Willing to come off medical therapy 4 weeks before and during study. 4. Willing to follow high/low saturated fat diet 5. Willing to attend dietary counseling sessions 6. Willing to attend frequent clinic visits 7. Subjects willing to participate under the conditions described in the informed consent form (ICF) and able to sign the ICF and applicable HIPAA forms.

Exclusion criteria

1. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins. Note: patients on thyroid replacement therapy can be included if the dosage of thyroxine has been stable for 6 weeks prior to the first study visit and thyroid-stimulating hormone (TSH) level is within the normal range. 2. Conditions of severe acute vascular stress (e.g. acute coronary syndrome, ischemic stroke, or major vascular surgery) within 3 months prior to the first study visit. 3. Patients unable to maintain their current activity level or planning to increase their activity level (e.g. new exercise regimen). 4. Pregnant or breast-feeding women. 5. Major illness 6. Secondary cause of dyslipidemia (e.g. obstructive liver disease, hypothyroidism, or nephrotic syndrome) 7. Hospitalization within 3 months 8. Substance abuse (illegal drug use, chronic alcoholism or problematic use of alcohol or total daily alcohol intake \>2 drinks per day in men and \> 1 drink per day in women). 9. Immunodeficiency or HIV-positive status 10. Illiteracy 11. Severe medical condition that may impair the ability of the person to participate in a nutrition intervention study (e.g. digestive disease with fat intolerance, advanced malignancy, or major neurological, psychiatric or endocrine disease) 12. Any other medical condition thought to limit survival to less than 1 year 13. Difficulties or major inconvenience to change dietary habits 14. History of food allergy with hypersensitivity to any of the components of olive oil or nuts

Design outcomes

Primary

MeasureTime frameDescription
Change in LDL-cholesterol4 weeksTo quantify the change in low density lipoprotein cholesterol

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026